钠-葡萄糖协同转运蛋白2抑制剂减少2型糖尿病患者心房颤动发生的作用机制研究进展

Research progress on the mechanism of action of sodium⁃glucose cotransporter⁃2 inhibitors reducing the occurrence of atrial fibrillation in patients with type 2 diabetes mellitus

心房颤动是临床常见心律失常之一,其发病率不断增加,并且是造成心脑血管不良事件的重要因素,严重危害人类健康。2型糖尿病(T2DM)是常见慢性病之一,可增加心房颤动风险。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为新型降糖药物和新型抗心力衰竭药物应用于临床,但对其抗心律失常的特性知之甚少,大量临床试验数据表明SGLT2i减少了T2DM患者心房颤动发生率。本综述总结了SGLT2i减少T2DM患者心房颤动发生的作用机制,还讨论了临床研究和Meta分析研究的最新数据,为心房颤动防治提供新思路。

Atrial fibrillation(AF)is one of the most common arrhythmias in clinical practice.Its incidence is increasing,and it is an important factor causing adverse cardiovascular and cerebrovascular events,which seriously endangeres human health.Type 2 diabetes mellitus(T2 DM)is one of the common chronic diseases,which can increase the risk of AF.Sodium⁃glucose cotransporter⁃2 inhibitors(SGLT2i)have been used in clinical practice as new hypoglycemic drugs and new anti⁃heart failure drugs,but little is known about their anti⁃arrhythmic properties.A large number of clinical trial data have shown that SGLT2i reduce the incidence of AF in patients with T2 DM.This review summarizes the mechanism of action of SGLT2i reducing the occurrence of AF in patients with T2 DM,and discusses the latest data from clinical studies and Meta⁃analysis studies,so as to provide new ideas for the prevention and treatment of AF.